Search company, investor...
Editas Medicine company logo

Editas Medicine

editasmedicine.com

Founded Year

2013

Stage

IPO | IPO

Total Raised

$163M

Date of IPO

2/3/2016

Market Cap

0.66B

Stock Price

11.26

About Editas Medicine

Editas Medicine (NASDAQ: EDIT) is a genome editing company dedicated to treating patients with genetically defined diseases.

Headquarters Location

11 Hurley Street

Cambridge, Massachusetts, 02141,

United States

617-401-9000

Missing: Editas Medicine's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Editas Medicine's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Editas Medicine

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Editas Medicine in 1 CB Insights research brief, most recently on Aug 31, 2021.

Article Thumbnail

Aug 31, 2021

What Is CRISPR?

Expert Collections containing Editas Medicine

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Editas Medicine is included in 3 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Editas Medicine Patents

Editas Medicine has filed 90 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Molecular biology
  • Genetic engineering
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/2/2017

1/31/2023

Small nuclear RNA, Molecular biology, Genetics, Biotechnology, Genetic engineering

Grant

Application Date

8/2/2017

Grant Date

1/31/2023

Title

Related Topics

Small nuclear RNA, Molecular biology, Genetics, Biotechnology, Genetic engineering

Status

Grant

Latest Editas Medicine News

Editas, Beam win bullish views as Cantor launches gene editing coverage

Feb 1, 2023

Natali_Mis Editas Medicine (NASDAQ: EDIT ), Intellia Therapeutics (NASDAQ: NTLA ), and Beam Therapeutics (NASDAQ: BEAM ) were among clinical-stage biotechs to receive Overweight ratings at Cantor Fitzgerald as the firm launched its coverage on several gene editing companies. The analyst Rick Bienkowski sees multiple catalysts for gene editing companies at a time when the subsector has underperformed the broader biotech space over the past 12 months due to regulatory uncertainties clouding their path to U.S. approval. Editas (EDIT: Citing a recent portfolio overhaul, Bienkowski issues a $15/share 12-month target for Editas ( EDIT ), arguing, “…we believe EDIT shares are well-positioned to appreciate in the coming year due to favorable IP positioning and expected clinical data updates.” In 2022, the U.S. patent officials backed its licensing partner Broad Institute over certain patents covering CRISPR/Cas9 gene editing in human cells. An appeals court ruling expected in H2 2023 over the decision can strengthen the company’s IP position paving the way for Editas ( EDIT ) to discuss sublicenses for CRISPR/Cas9-based medicines, Bienkowski noted. Intellia ( NTLA ): Meanwhile, the analyst points out that Intellia ( NTLA ) has established proof of concept for its lead programs NTLA-2001 and NTLA-2002 in TTR amyloidosis (ATTR) and hereditary angioedema (HAE) prophylaxis, respectively. Issuing a $67 per share target on the stock, Bienkowski argues that as the company plans to launch U.S. trial sites for NTLA-2002, a potential clearance of its clinical trial application along with more data for NTLA-2001 could drive Intellia ( NTLA ) higher over the next 12 months. In 2021 Intellia ( NTLA ) and Regeneron (NASDAQ: REGN ) drove gene editing stocks higher as early data from a Phase 1 trial for NTLA-2001 in ATTR indicated the potential of in-vivo CRISPR genome editing for the first time in humans. Beam ( BEAM ): Cantor estimates a $62/share 12-month target for Beam ( BEAM ), arguing that the company’s base-editing technology allows it to develop “novel medicines that are highly differentiated from competing therapies.” The analyst notes that Beam’s ( BEAM ) partner Verve Therapeutics (NASDAQ: VERV ), plans to report Phase 1 data for its lead asset VERVE-101 in heterozygous familial hypercholesterolemia (HeFH) in H2 2023, generating the first patient data for a base-editing therapy. The readout “could broadly validate BEAM’s pipeline if positive and serve as an inflection point for BEAM shares in 2H23,” Bienkowski wrote. Verve ( VERV ): However, he issued a Neutral rating and $21 per share target for Verve ( VERV ), citing increased clinical and commercial risk linked to gene editing therapies targeted at large indications compared to other gene editing programs. The company has suffered a setback in its plans for lead asset VERVE-101 for heterozygous familial hypercholesterolemia in the U.S. as the FDA has issued a clinical hold on its Investigational New Drug application (IND). Read: According to Seeking Alpha contributor Star Investments, Intellia ( NTLA ) “is considered the best gene editing company” given its first mover advantage in vivo gene editing. Recommended For You

Editas Medicine Frequently Asked Questions (FAQ)

  • When was Editas Medicine founded?

    Editas Medicine was founded in 2013.

  • Where is Editas Medicine's headquarters?

    Editas Medicine's headquarters is located at 11 Hurley Street, Cambridge.

  • What is Editas Medicine's latest funding round?

    Editas Medicine's latest funding round is IPO.

  • How much did Editas Medicine raise?

    Editas Medicine raised a total of $163M.

  • Who are the investors of Editas Medicine?

    Investors of Editas Medicine include Deerfield Management, Fidelity Investments, Omega Funds, Khosla Ventures, Casdin Capital and 18 more.

  • Who are Editas Medicine's competitors?

    Competitors of Editas Medicine include Redpin Therapeutics and 4 more.

Compare Editas Medicine to Competitors

G
GeneTether

GeneTether is an early-stage biotechnology company developing improved gene-editing technologies using Crispr/Cas, TALEN, and Zinc-Finger nucleases for human therapeutic applications.

C
CODA Biotherapeutics

CODA Biotherapeutics is a preclinical-stage biopharmaceutical company developing a chemogenetic gene therapy platform for the treatment of intractable diseases. Its platform aims to control the activity of neurons to treat disease. With chemogenetics, target neuronal populations are modified using gene therapy to express a tunable ligand-gated ion channel. These ligand-gated ion channels are engineered to be highly responsive to a specific proprietary small molecule but are otherwise inactive. The interaction of the small molecule and engineered receptor allow for dose-dependent control of the neurons to generate therapeutic effect.

S
Shape Therapeutics

Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs).

R
Rznomics

Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. Rznomics was founded in 2017 and is based in Yongin-si, South Korea.

C
CorriXR Therapeutics

CorriXR Therapeutics is an oncology-focused biotherapeutics development company that develops gene editing platform technology. It focuses on the treatment of squamous cell carcinoma of the lung. The company was founded in 2022 and is based in Newark, Delaware.

Intellia Therapeutics Logo
Intellia Therapeutics

Intellia Therapeutics (NASDAQ: NTLA) is developing genome editing therapies that use CRISPR/Cas9 technology to cure genetic diseases with simple, targeted treatments.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.